Laura Cohen
Vice President, Alzheimer's Environment Shaping, Lilly Neuroscience Eli Lilly & Co.
Seminars
Thursday 5th February 2026
Market Access Reality Check for Disease Modifying AD Drugs
4:00 pm
- CMS coverage gap for pre clinical anti amyloids and spill over to private payers
- Cost drivers: MRI monitoring, infusion logistics and diagnostic bundling
- Generating evidence packages that HTA bodies prioritise (QoL, caregiver, budget impact) with responsible data storytelling to maintain policymaker trust
